ZA201002356B - Xinafoate salt of n4-(2,2-difluoro-4h-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3-(methylaminocar bonylmethyleneoxy)phenyl]2,4-pyrimidinediamine - Google Patents
Xinafoate salt of n4-(2,2-difluoro-4h-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3-(methylaminocar bonylmethyleneoxy)phenyl]2,4-pyrimidinediamineInfo
- Publication number
- ZA201002356B ZA201002356B ZA2010/02356A ZA201002356A ZA201002356B ZA 201002356 B ZA201002356 B ZA 201002356B ZA 2010/02356 A ZA2010/02356 A ZA 2010/02356A ZA 201002356 A ZA201002356 A ZA 201002356A ZA 201002356 B ZA201002356 B ZA 201002356B
- Authority
- ZA
- South Africa
- Prior art keywords
- bonylmethyleneoxy
- methylaminocar
- pyrimidinediamine
- oxazin
- difluoro
- Prior art date
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 229950000339 xinafoate Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97003007P | 2007-09-05 | 2007-09-05 | |
| PCT/IB2008/002288 WO2009031011A2 (en) | 2007-09-05 | 2008-08-27 | Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201002356B true ZA201002356B (en) | 2010-12-29 |
Family
ID=40293576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2010/02356A ZA201002356B (en) | 2007-09-05 | 2010-04-01 | Xinafoate salt of n4-(2,2-difluoro-4h-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3-(methylaminocar bonylmethyleneoxy)phenyl]2,4-pyrimidinediamine |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8193181B2 (enExample) |
| EP (1) | EP2215087B1 (enExample) |
| JP (1) | JP2009084270A (enExample) |
| KR (2) | KR20120120453A (enExample) |
| CN (1) | CN101861314B (enExample) |
| AR (1) | AR068369A1 (enExample) |
| AU (1) | AU2008294473B2 (enExample) |
| BR (1) | BRPI0816278A2 (enExample) |
| CA (1) | CA2697495C (enExample) |
| ES (1) | ES2452965T3 (enExample) |
| IL (1) | IL203973A (enExample) |
| MX (1) | MX2010002518A (enExample) |
| NZ (1) | NZ583582A (enExample) |
| RU (1) | RU2458925C2 (enExample) |
| TW (1) | TWI371277B (enExample) |
| WO (1) | WO2009031011A2 (enExample) |
| ZA (1) | ZA201002356B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010250923A1 (en) | 2009-05-21 | 2011-11-17 | Astrazeneca Ab | Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases |
| GB0908772D0 (en) * | 2009-05-21 | 2009-07-01 | Astrazeneca Ab | New salts 756 |
| EP2706852B1 (en) | 2011-05-10 | 2018-08-22 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
| JP2014513687A (ja) | 2011-05-10 | 2014-06-05 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｓｙｋ阻害薬としてのピリジルアミノピリジン |
| EP2706853B1 (en) | 2011-05-10 | 2017-06-14 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
| US8987456B2 (en) | 2011-10-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
| EP2763974B1 (en) | 2011-10-05 | 2016-09-14 | Merck Sharp & Dohme Corp. | Phenyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| EP2763976B1 (en) | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| EP2768480A1 (en) * | 2011-10-21 | 2014-08-27 | Rigel Pharmaceuticals, Inc. | Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4]oxazin-3-one) -6-yl]-5-fluoro-n2- [3- (methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine |
| WO2013192128A1 (en) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Imidazolyl analogs as syk inhibitors |
| EP2863914B1 (en) | 2012-06-20 | 2018-10-03 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
| EP2863915B1 (en) | 2012-06-22 | 2017-12-06 | Merck Sharp & Dohme Corp. | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| WO2013192098A1 (en) | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| WO2014031438A2 (en) | 2012-08-20 | 2014-02-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| WO2014048065A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
| US9624210B2 (en) | 2012-12-12 | 2017-04-18 | Merck Sharp & Dohme Corp. | Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors |
| EP2934525B1 (en) | 2012-12-21 | 2019-05-08 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors |
| RU2720412C2 (ru) * | 2013-03-14 | 2020-04-29 | Аллерган, Инк. | Композиции доставки с замедленным высвобождением и способ стабилизации белков в процессе изготовления |
| US9745295B2 (en) | 2013-04-26 | 2017-08-29 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| EP2988749B1 (en) | 2013-04-26 | 2019-08-14 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors |
| US9670196B2 (en) | 2013-12-20 | 2017-06-06 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors |
| EP3082807B1 (en) | 2013-12-20 | 2018-07-04 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| WO2015095445A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| WO2015138273A1 (en) | 2014-03-13 | 2015-09-17 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
| WO2018189566A1 (en) * | 2017-04-10 | 2018-10-18 | Dorian Bevec | Use of a chemical compound as a therapeutic agent |
| EP3823964A1 (en) * | 2018-07-18 | 2021-05-26 | Astrazeneca AB | A xinafoate salt of a jak inhibiting compound |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| GB9808802D0 (en) * | 1998-04-24 | 1998-06-24 | Glaxo Group Ltd | Pharmaceutical formulations |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0208609D0 (en) * | 2002-04-13 | 2002-05-22 | Glaxo Group Ltd | Compositions |
| EP1546120A4 (en) * | 2002-10-04 | 2006-11-22 | Pharmacia Corp | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE |
| US7122542B2 (en) * | 2003-07-30 | 2006-10-17 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
| NZ564697A (en) * | 2005-06-15 | 2010-04-30 | Boehringer Ingelheim Int | Process for preparing tiotropium salts, tiotropium salts as such and pharmaceutical compositions thereof |
| MX2008016542A (es) | 2006-06-30 | 2009-01-19 | Novartis Ag | Derivados de quinolina y sus composiciones farmaceuticas. |
-
2008
- 2008-08-27 KR KR1020127024371A patent/KR20120120453A/ko not_active Withdrawn
- 2008-08-27 CA CA2697495A patent/CA2697495C/en not_active Expired - Fee Related
- 2008-08-27 NZ NZ583582A patent/NZ583582A/en not_active IP Right Cessation
- 2008-08-27 EP EP08806983.6A patent/EP2215087B1/en not_active Not-in-force
- 2008-08-27 AU AU2008294473A patent/AU2008294473B2/en not_active Ceased
- 2008-08-27 KR KR1020107007283A patent/KR101225233B1/ko not_active Expired - Fee Related
- 2008-08-27 RU RU2010108162/04A patent/RU2458925C2/ru active
- 2008-08-27 US US12/676,075 patent/US8193181B2/en not_active Expired - Fee Related
- 2008-08-27 BR BRPI0816278A patent/BRPI0816278A2/pt not_active Application Discontinuation
- 2008-08-27 CN CN200880105757XA patent/CN101861314B/zh not_active Expired - Fee Related
- 2008-08-27 WO PCT/IB2008/002288 patent/WO2009031011A2/en not_active Ceased
- 2008-08-27 ES ES08806983.6T patent/ES2452965T3/es active Active
- 2008-08-27 MX MX2010002518A patent/MX2010002518A/es active IP Right Grant
- 2008-09-03 JP JP2008225403A patent/JP2009084270A/ja active Pending
- 2008-09-04 AR ARP080103848A patent/AR068369A1/es unknown
- 2008-09-04 TW TW097133970A patent/TWI371277B/zh not_active IP Right Cessation
-
2010
- 2010-02-15 IL IL203973A patent/IL203973A/en active IP Right Grant
- 2010-04-01 ZA ZA2010/02356A patent/ZA201002356B/en unknown
-
2012
- 2012-05-09 US US13/467,850 patent/US8486935B2/en not_active Expired - Fee Related
-
2013
- 2013-06-18 US US13/920,434 patent/US20130281446A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20120316160A1 (en) | 2012-12-13 |
| AU2008294473B2 (en) | 2013-12-05 |
| NZ583582A (en) | 2012-02-24 |
| IL203973A (en) | 2013-10-31 |
| JP2009084270A (ja) | 2009-04-23 |
| US20100204232A1 (en) | 2010-08-12 |
| BRPI0816278A2 (pt) | 2015-09-22 |
| EP2215087A2 (en) | 2010-08-11 |
| AR068369A1 (es) | 2009-11-11 |
| EP2215087B1 (en) | 2013-12-18 |
| TW200927125A (en) | 2009-07-01 |
| CN101861314B (zh) | 2013-07-24 |
| ES2452965T3 (es) | 2014-04-03 |
| CA2697495C (en) | 2013-02-05 |
| US20130281446A1 (en) | 2013-10-24 |
| KR101225233B1 (ko) | 2013-01-22 |
| US8486935B2 (en) | 2013-07-16 |
| WO2009031011A2 (en) | 2009-03-12 |
| CA2697495A1 (en) | 2009-03-12 |
| MX2010002518A (es) | 2010-03-26 |
| KR20100049688A (ko) | 2010-05-12 |
| AU2008294473A1 (en) | 2009-03-12 |
| KR20120120453A (ko) | 2012-11-01 |
| WO2009031011A3 (en) | 2009-04-30 |
| US8193181B2 (en) | 2012-06-05 |
| RU2458925C2 (ru) | 2012-08-20 |
| TWI371277B (en) | 2012-09-01 |
| HK1144685A1 (en) | 2011-03-04 |
| RU2010108162A (ru) | 2011-09-10 |
| CN101861314A (zh) | 2010-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201002356B (en) | Xinafoate salt of n4-(2,2-difluoro-4h-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3-(methylaminocar bonylmethyleneoxy)phenyl]2,4-pyrimidinediamine | |
| IL210195A (en) | Benzoxazines, benzazazines, and related compounds with nos inhibitory activity, medicinal preparations and their use | |
| IL219718A (en) | Compounds 3– (3, 4 – Dihydro-2h - Benzo [4,1] oxazin-6-moiety) –1h - Pyrimidine-2, 4 –Dion, their preparation and herbicides containing them | |
| PL2003132T3 (pl) | Pochodne oksadiazolu jako agoniści S1P1 | |
| IL199110A (en) | An herbicide containing isoxazole derivative | |
| IL196959A0 (en) | Insecticidal isoxazolines | |
| SI2252300T1 (sl) | Uporaba 2,4-pirimidindiaminov za zdravljenje ateroskleroze | |
| IL196697A (en) | Use of 4 Hydroxy-Alpha-Phenyl Butyl Nitron or its Derivatives to Prepare a Cure for Sensory-Neural Hearing Loss | |
| PT2136748T (pt) | Transplante da córnea | |
| IL196688A0 (en) | Synthetic cornea from retinal stem cells | |
| EP1988899A4 (en) | ARIPIPRAZOLE-CO-CRYSTALS | |
| SI2125714T1 (sl) | Hidrokloridna sol 5-(3-(3-hidroksifenoksi)azetidin-1-il)-5-metil-2,2-difenilheksanamida | |
| IL209423A0 (en) | 4,5-dihydro-oxazol-2-yl derivatives | |
| IL183379A0 (en) | Processes for the preparation of linezolid intermediate | |
| GB0700786D0 (en) | Morpholine dopamine agonists for the treatment of pain | |
| EP1942734A4 (en) | PREPARATION OF THE APREPITANT | |
| PL2319517T3 (pl) | Wykorzystanie proleku do podawania doocznego, śródszklistkowego | |
| EP2069339A4 (en) | SUBSTITUTED PIPERIDINOPHENYLOXAZOLIDINONE | |
| ZA201005306B (en) | 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use | |
| IL199239A0 (en) | Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6- | |
| HK1152943A (en) | Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity | |
| GB0714303D0 (en) | Use of compounds for preparing anti-tuberculosis agents | |
| GB0712458D0 (en) | Use of compounds for preparing anti-tuberculosis agents | |
| GB0607322D0 (en) | Disposable blade adaption | |
| AU4913P (en) | KencoralGL Kennedia coccinea |